National Consensus Standards for Behavioral Health Conditions

Transcription

1 National Consensus Standards for Behavioral Health Conditions an unofficial introduction David Pating, MD Chief, Addiction Medicine Kaiser San Francisco Associate Clinical Professor UCSF Member, NQF Behavioral Health Standing Committee April 27, 2017

2

3 The National Quality Forum: A Unique Role Established in 1999, NQF is a non-profit, non-partisan, membership-based organization that brings together public and private sector stakeholders to reach consensus on healthcare performance measurement. The goal is to make healthcare in the U.S. better, safer, and more affordable. Mission: To lead national collaboration to improve health and healthcare quality through measurement An Essential Forum Gold Standard for Quality Measurement Leadership in Quality Unauthorized presentation for demonstration purposes only. 3

4 NQF Activities in Multiple Measurement Areas Performance Measure Endorsement 600+ NQF-endorsed measures across multiple clinical areas 19 empaneled standing committees Measure Applications Partnership (MAP) Advises HHS on selecting measures for 20+ federal programs, Medicaid, and health exchanges National Quality Partners Convenes stakeholders around critical health and healthcare topics Spurs action on patient safety, early elective deliveries, and other issues Measurement Science Convenes private and public sector leaders to reach consensus on complex issues in healthcare performance measurement such as attribution, alignment, sociodemographic status (SDS) adjustment 4

5 CDP-MAP INTEGRATION INFORMATION FLOW NQF endorsement evaluation NQF outreach to MUC developers in February and during Call for Measures Funding proposals include MAP topics MAP feedback to Committee MAP feedback on endorsed measures: Entered into NQF database Shared with Committee during maintenance Ad hoc review if MAP raises any major issues addressing criteria for endorsement NQF evaluation summary provided to MAP MUC given conditional support pending NQF endorsement MAP pre-rulemaking recommendations MUC that has never been through NQF 5

6 Types of Performance Measures Quality Resource use/cost Efficiency (combination of quality and resource use) Composite (two or more measures in a single score) NQF endorsement reflects rigorous scientific and evidence-based review for Standardized performance measures are used for comparisons. 6

7 Characteristics of Measures Measures are different from concepts or ideas» Quality of care is an abstract construct» A quality measure is a numeric quantification of healthcare quality Measures have detailed specifications» What to count (including codes, definitions)» Who is included and/or excluded» When to count» Where to find data» How to compute score Numerators Denominators = X Y 7

8 8

9 Person-Centered Measures 9

10 Behavioral Health Portfolio of MUC measures: 4 *Measures for maintenance evaluation 0008: Experience of Care and Health Outcomes (ECHO) Survey (behavioral health, managed care versions) (CMS)* 0027: Medical Assistance With Smoking and Tobacco Use Cessation (NCQA)* 0028: Preventive Care & Screening: Tobacco Use: Screening & Cessation Intervention (PCPI Foundation)* 3185: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention (emeasure) (PCPI Foundation) 0108: Follow-Up Care for Children Prescribed ADHD Medication (NCQA)* 0576: Follow-Up After Hospitalization for Mental Illness (NCQA)* 3132: Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan (emeasure) (CMS) 3148: Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan (CMS)* 3172: Continuity of Pharmacotherapy for Alcohol Use Disorder (RAND Corporation) 3175: Continuity of Pharmacotherapy for Opioid Use Disorder (RAND Corporation) NQF currently has more than 50 endorsed measures within the area of behavioral health. Endorsed measures undergo periodic evaluation to maintain endorsement maintenance. 10

11 Measure Evaluation Criteria Overview 11

12 NQF Consensus Development Criteria Criteria #1: Importance to Measure and Report* Criteria #2: Scientific Acceptability of Measure Properties* Criteria #3: Feasibility Criteria #4: Usability and Use *=(must-pass) Criteria #5: Comparison to Related or Competing Measures Final Recommendation for Endorsement/Harmonization 12

13 Criterion #1: Importance to Measure & Report 1. Importance to measure and report - Extent to which the specific measure focus is evidence-based and important to making significant gains in healthcare quality where there is variation in or overall less-than-optimal performance. 1a. Evidence: the measure focus is evidence-based 1b. Opportunity for Improvement: demonstration of quality problems and opportunity for improvement, i.e., data demonstrating considerable variation, or overall less-than-optimal performance, in the quality of care across providers; and/or disparities in care across population groups 1c. Quality construct and rationale (composite measures only) 13

14 Subcriterion 1a: Evidence for Measure Focus Hierarchical preference for Outcomes linked to evidence-based processes/structures Outcomes of substantial importance with plausible process/structure relationships Intermediate outcomes Processes/structures Most closely linked to outcomes 14

15 Criterion #2: Reliability and Validity Scientific Acceptability of Measure Properties Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of health care delivery 2a. Reliability (must-pass) 2a1. Precise specifications including exclusions 2a2. Reliability testing data elements or measure score 2b. Validity (must-pass) 2b1. Specifications consistent with evidence 2b2. Validity testing data elements or measure score 2b3. Justification of exclusions relates to evidence 2b4. Risk adjustment typically for outcome/cost/resource use 2b5. Identification of differences in performance 2b6. Comparability of data sources/methods 2b7. Missing data 15

16 Reliability and Validity Assume the center of the target is the true score Consistent, but wrong Inconsistent & wrong Consistent & correct 16

17 Criterion #3: Feasibility Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. 3a: Clinical data generated during care process 3b: Electronic sources 3c: Data collection strategy can be implemented 17

18 Criterion #4: Usability and Use Extent to which potential audiences are using or could use performance results for both accountability and performance improvement to achieve the goal of high-quality, efficient healthcare for individuals or populations. 4a: Accountability and Transparency 4b: Improvement 4c: Benefits outweigh the harms 4d: Vetting by those being measured and others 18

19 Criterion #1: Importance to measure and report Criteria emphasis is different for new vs. maintenance measures New measures Evidence Quantity, quality, consistency (QQC) Established link for process measures with outcomes Maintenance measures DECREASED EMPHASIS: Require measure developer to attest evidence is unchanged evidence from last evaluation; Standing Committee to affirm no change in evidence IF changes in evidence, the Committee will evaluate as for new measures Gap opportunity for improvement, variation, quality of care across providers INCREASED EMPHASIS: data on current performance, gap in care and variation 19

20 Criterion #2: Scientific Acceptability New measures Measure specifications are precise with all information needed to implement the measure Reliability Validity (including riskadjustment) Maintenance measures NO DIFFERENCE: Require updated specifications DECREASED EMPHASIS: If prior testing adequate, no need for additional testing at maintenance with certain exceptions (e.g., change in data source, level of analysis, or setting) Must address the questions for SDS Trial Period 20

21 Criteria #3-4: Feasibility and Usability and Use New measures Feasibility Measure feasible, including emeasure feasibility assessment Usability and Use Use: used in accountability applications and public reporting Usability: impact and unintended consequences Maintenance measures NO DIFFERENCE: Implementation issues may be more prominent INCREASED EMPHASIS: Much greater focus on measure use and usefulness, including both impact and unintended consequences 21

22 Recommendation for Endorsement or Endorsement + The Committee votes on whether to recommend a measure for NQF Endorsement Or Endorsement + designation, indicating that the measure exceeds NQF criteria if Meets evidence criteria without exception Good results on reliability testing of the measure score Good results on empirical validity testing of the measure score (not just face validity) Well-vetted in real world settings by those being measured and others in key areas. Harmonization of related or competing measures 22

23 23

24 The Business of Making Measures 24

25 25

26 Busy Clinic - The App! 26

27 27

28 28

29 29

30 Behavioral Health Standing Committee Peter Briss, MD, MPH, (Co- Chair) Harold Pincus, MD (Co-Chair) Robert Atkins, MD, MPH Mady Chalk, PhD, MSW Shane Coleman, MD, MPH* David Einzig, MD Julie Goldstein Grumet, PhD Charles Gross, PhD* Constance Horgan, ScD Lisa Jensen, DNP, APRN Dolores (Dodi) Kelleher, MS, DMH Kraig Knudsen, PhD Michael R. Lardieri, LCSW Tami Mark, PhD, MBA Raquel Mazon Jeffers, MPH, MIA Bernadette Melnk, PhD, RN, CPNP/FAANP, FNAP, FAAN Laurence Miller, MD Brooke Parish, MD* David Pating, MD Vanita Pindolia, PharmD Rhonda Robinson Beale, MD Lisa Shea, MD, DFAPA Andrew Sperling, JD* Jeffery Susman, MD Michael Trangle, MD Bonnie Zima, MD, MPH Leslie S. Zun, MD, MBA *indicates new committee member 30

31 31

32 Evidence: Gap 32

33 33

34 Evidence Validity 34

35 35

36 Feasibility Useability 36

37 Review of HEDIS: AOD_IET Measure The percentage of adolescent and adult members with a new episode of alcohol or other drug (AOD) dependence* (first visit in calendar year) who received the following: Index Episode Start Date (IESD) 14 days inclusive Primary Focus Inpatient Intensive Outpatient Partial Hospitalization Outpatient Detoxification ED Encounter Initiation Visit 30 days Inpatient Intensive Outpatient Partial Hospitalization Outpatient HEDIS dependence definition is very broad and contains almost all alcohol and substance related codes (see appendix) Two Engagement Visits Inpatient Intensive Outpatient Partial Hospitalization Outpatient

38 Unhealthy Drinking In KPNC Primary Care Need Specialty Treatment Brief Intervention Alcohol Dependent 0.8% Unhealthy Drinkers w/out dependence 6.8% 7.5% Low-Risk Drinkers Abstainers Institute of Medicine. 1990, and World Health Organization,

39 20 Most Frequent Dx in Med-FMS 2013 Diagnoses 2013 # Index Visits % Initiated 1 ALCOHOL ABUSE % 2 ALCOHOL DEPENDENCE % 3 ALCOHOL USE, EXCESSIVE, NON-DEPENDENT % 4 OPIOID DEPENDENCE % 5 CANNABIS DEPENDENCE 455 6% 6 CANNABIS ABUSE 428 7% 7 SUBSTANCE ABUSE % 8 ALCOHOL DEPENDENCE, CONTINUOUS 184 9% 9 DRUG DEPENDENCE % 10 DRUG ABUSE % 11 ALCOHOLISM % 12 OPIOID WITHDRAWAL % 13 DRUG SEEKING BEHAVIOR % 14 CAFFEINE USE 119 2% 15 ALCOHOL ABUSE, EPISODIC 96 16% 16 OPIOID DEPENDENCE, CONTINUOUS 94 12% 17 CAFFEINE DEPENDENCE 81 5% 18 METHAMPHETAMINE DEPENDENCE 81 11% 19 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPEND 79 11% 20 POLYSUBSTANCE ABUSE 71 11% Contact: Sue Paulsen QOS

40 HEDIS IET AOD 40

41 Approved for CMS: January

42 AUDIT Screening Tool Alcohol Use Disorders Identification Test Domain Question Hazardous Alcohol Use (1-3) Dependence Syndromes (4-6) Harmful Alcohol Use (7-10) AUDIT Score WHO Kaiser <8 (Alc Education) No Action 8-15 (Simple Advice) RN Advice >16 (Brief Counsel) LCSW&MD inbasket >20 (Specialist Tx)

43 Rx: Medication Recommendation 1. Naltrexone Injectable Extended Release (Vivitrol) 380mg IM a. Hold if LFT > 3x normal or recent opioid use. b. If decides against IM, consider oral Naltrexone 50mg daily. (#30) 2. Topiramate (second choice) a. Start 50mg hs x 1 week, then increase 100mg hs. (#50) b. Reduce dose ½ in renal disease. Caution: sedation.

44 Compared with other medications for alcohol use disorders, XR-NTX is associated with increased days on medication and lower utilization and cost of inpatient and emergency care. Aetna, 2011: XR-NTX (n=211) Disulfiram (1043), Oral NTX (1408), Acamprosate (2479) Bryson WC1, McConnell J, Korthuis PT, McCarty D. Extended-release naltrexone for alcohol dependence: persistence and healthcare costs and utilization., Am J Manag Care Jun;17 Suppl 8:S

45

46 JC SUB 1 46

47 JC SUB 2 47

48 JC SUB 3 48

49 49

50 50

51 51

52 Curative Factors in Addiction Treatment Cognitive Skills Training Identity & Self-Efficacy Anti-Craving Medications A Behavioral Program of Recovery Mind/Body Stress Mgt Sober Social Networks 4/27/

53 Resilience-based Addiction Treatment Values (Life of Meaning & Purpose) Alcoholis m Motivational Interviewing Anti-Craving Medications Cognitive skills (Mastery) Emotional Regulatio n (Serenity) Generalized Resilience Resources Self-Concept (Acceptance) Social Support (Belonging) A Behavioral Program of Recovery AA/Spirituality Relationships Hobby/Passio n QOL Assessment 4/27/

54 TEA

55 BAM

56

57 Measuring Progress: TEMT-KP 4/27/

58 58

59 Questions? 59